News

It will now be evaluated against wild type and Tamiflu (oseltamivir)-resistant H7N9 influenza virus under the DEA (Data Exchange Agreement) Annex for Medical Preparedness and Bio-Defense Agreement between

The document is released for public consultation until 31 August 2014. The aim of the proposal is not only to facilitate a rapid and smooth agreement of an

Multiple tumor types will be explored in the study, which could potentially include non-small cell lung cancer (NSCLC), metastatic melanoma, ovarian, colorectal (CRC) and squamous cell head and

Pernix’s team of approximately 90 specialty sales professionals will support the sales and marketing of Treximet. Doug Drysdale, Chairman, President and CEO of Pernix noted the acquisition of

The Phase I/II oncology trial is designed to assess the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1

The new global CoLaborator concept is aimed at providing young companies in the area of chemistry and biosciences ready-to-use laboratory and office infrastructure in the immediate vicinity of

The trial is a Phase I, open label, dose escalation study of immunoconjugate L-DOS47 in combination with vinorelbine in patients with metastatic or advanced solid tumors. Helix president

The deal will allow Novozymes to provide the pharma industry serum stable albumin drug conjugates with improved pharmacokinetic and/or targeting capabilities. Under the deal, Novozymes’ customers will be

The deal includes an option to acquire the technology during clinical development. Along with the June 2013 acquisition of Synacthen, the new deal expands the company’s portfolio of